세계의 황반부종 시장(2024-2031년)

Overview

The Global Macular Edema Market reached US$ 7,932.69 million in 2023 and is expected to reach US$ 14,874.70 million by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.

Macular edema is swelling in part of the retina (the light-sensitive layer of tissue at the back of your eye). People with macular edema may have blurry vision, but treatment can help reduce the swelling and prevent vision loss.

Macular edema happens when blood vessels leak into a part of the retina called the macula. This makes the macula swell, causing blurry vision. Many different conditions can cause macular edema. The most common one is diabetic retinopathy - an eye condition that causes vision loss in people with diabetes. When diabetic retinopathy causes macular edema, it is called diabetic macular edema (DME).

Blurry vision and vision that gets worse over time are the main symptoms of macular edema. Generally, detection of macular edema is done by fluorescein angiogram, optical coherence tomography (OCT), and amsler grid methods.

Market Dynamics: Drivers

Rising prevalence of diabetes in various age groups

Multiple factors drive the demand for the global macular edema market. The rising prevalence of diabetes propels the market growth. Nowadays people affected by diabetes are increasing a lot which is a major cause for the rise of macular edema in people.

Diabetic macular edema is one of the most frequently recorded cases in the overall macular edema cases. According to NCBI, in the US, 3.8% of people who are above the age of 40 years and suffer from diabetes, suffer from diabetic macular edema. In the entire global population who suffer from diabetes, around 4 - 7% of people are being affected by diabetic macular edema.

Restraints

The global macular edema market also faces several challenges and restraints. One key restraint is the high cost of macular edema treatments and therapies, which can limit access to care for patients, particularly in low-income and underserved communities. Additionally, regulatory hurdles and reimbursement policies may create barriers to the adoption of new diabetic macular edema treatments, delaying access to innovative therapies for patients in need. Furthermore, the complex nature of DME and its multifactorial pathogenesis present challenges for developing targeted and effective treatment strategies.

Market Segment Analysis

The global macular edema market is segmented based on disease type, treatment type, end-users, and region.

The segment laser treatment accounted for approximately 56.4% of the global macular edema market share

Laser surgery of the eye is among the most frequently used therapy techniques that are applied to treat macular edema. This is among the safest techniques that can be used to address macular edema, thus the significance of this viewpoint. The Conventional and/or Laser treatment has the following benefits, it slows down the development or reduces macular edema. Free-standing treatments include focal/grid photocoagulation or photodynamic therapy (PDT) which formed strategies for two purposes. The first one was attempted to reduce the swelling (edema) that develops in the macula area of the retina, which is responsible for sharpness.

Laser treatment helps to stop vision from getting any worse because the procedure helps reduce macular edema while having a considerably beneficial impact on the health of the retina. This about is important in conditions such as DME where if the condition is left untreated, the individual will progressively lose their vision. According to National Eye Institute, by treatment 50 to 60% of the macular edema cases can be completely cured without any side effects.

Market Geographical Share

North America accounted for approximately 43.2% of the global macular edema market share

North America region is expected to hold the largest market share over the forecast period. The rising incidence of macular edema, and growing awareness among people, in this region, help to propel the market.

Diabetic Macular Edema (DME) is a significant contributor to macular edema cases in North America due to the high prevalence of diabetes. Approximately 7.7 million people in the United States are estimated to have diabetic retinopathy, a condition that can lead to DME. Overall, macular edema can occur due to various causes including retinal vein occlusion and inflammatory conditions, but diabetic retinopathy remains a primary driver in this region.

In urban centers with advanced healthcare facilities, the adoption of newer treatments like anti-VEGF injections may be more prevalent due to better access to specialists and resources. The regulatory landscape in North America (specifically in the United States and Canada) is robust, ensuring that new therapies undergo rigorous evaluation before approval. This process helps maintain high standards of safety and efficacy in treatments for macular edema.

Market Segmentation

By Disease Type

Diabetic macular edema

Cystoid macular edema

By Treatment Type

Injections

Eye Drops

Laser Treatment

Eye surgery

By End Users

Hospitals and clinics

Ophthalmology centers

Research institutes and Laboratories

Others

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the globular macular edema market include Novartis Pharmaceuticals, Regeneron Pharmaceuticals, Roche, Allergan (AbbVie), Bayer, Alimera Sciences, Bausch Lomb, Genentech, Santen Pharmaceutica, and Ophthotech Corporation.

Key Developments

In September 2023, Genentech is developing a Port Delivery System (PDS) that continuously delivers a customized formulation of ranibizumab (Lucentis) directly into the eye over extended periods. This approach aims to reduce the treatment burden for patients with nAMD and potentially other retinal diseases, including macular edema, by providing sustained delivery of the drug and minimizing the need for frequent injections.

In March 2023, Santen Pharmaceuticals announced Positive Phase 3 Results for DE-128 (Sirolimus). Santen reported positive topline results from the Phase 3 DERBY study evaluating DE-128 (sirolimus) intravitreal injection for the treatment of non-infectious uveitis. Sirolimus is an mTOR inhibitor that suppresses inflammation and neovascularization in the eye. The study showed significant improvements in visual acuity and reduction in central subfield thickness compared to sham injections, demonstrating potential benefits in treating macular edema associated with uveitis.

Why Purchase the Report?

To visualize the global macular edema market segmentation based on disease type, treatment type, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of global macular edema market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping is available in Excel consisting of key products of all the major players.

The global macular edema treatment market report would provide approximately 62 tables, 52 figures, and 181 Pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Type
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing prevalence of diabetes in all age groups
    • 4.1.1.2. Increase in aging of the overall global population
  • 4.1.2. Restraints
    • 4.1.2.1. High cost of treatment
    • 4.1.2.2. The treatment procedures are complicated
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. By Disease Type

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 6.1.2. Market Attractiveness Index, By Disease Type
• 6.2. Diabetic macular edema
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Cystoid macular edema

7. By Treatment Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 7.1.2. Market Attractiveness Index, By Treatment
• 7.2. Injections
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Eye drops
• 7.4. Laser treatment
• 7.5. Eye surgery

8. By End-Users

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-users
  • 8.1.2. Market Attractiveness Index, By End-Users
• 8.2. Ophthalmology centers
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Research institutes and laboratories
• 8.4. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. The U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. UK
    • 9.3.6.3. France
    • 9.3.6.4. Italy
    • 9.3.6.5. Spain
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Novartis pharmaceuticals *
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Regeneron pharmaceuticals
• 11.3. Roche
• 11.4. Allergan (ABBVie)
• 11.5. Bayer
• 11.6. Alimera sciences
• 11.7. Bausch Lomb
• 11.8. Genentech
• 11.9. Santen Pharmaceuticals
• 11.10. Opthotech Corporation (*LIST NOT EXHAUSTIVE)

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us